All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 20, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 11

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Health Issues

Issues related to compounding and counterfeit drugs. H.R. 2715, Destruction of Hazardous Imports Act.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to coverage of anti-obesity medications. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Monitored issues related to the implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes and foreign-based multinationals. Monitor OECD negotiations on the Pillar II global minimum tax.

Trade (domestic/foreign)

Issues related to tariffs. Issues related to importation of counterfeit drugs.

Bills named in this filing 3

H.R. 2715
Destruction of Hazardous Imports Act
H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.